SEARCH

SEARCH BY CITATION

References

  • Abi-Dargham A., Gil R., Krystal J., Baldwin R. M., Seibyl J. P., Bowers M., van Dyck C. H., Charney D. S., Innis R. B. and Laruelle M. (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 155, 761767.
  • Antonini A., Barone P., Ceravolo R., Fabbrini G., Tinazzi M. and Abbruzzese G. (2010) Role of pramipexole in the management of Parkinson's disease. CNS Drugs 24, 829841.
  • Aoyama S., Kase H. and Borrelli E. (2000) Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J. Neurosci. 20, 58485852.
  • Bernard V., Normand E. and Bloch B. (1992) Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J. Neurosci. 12, 35913600.
  • Betty M., Harnish S. W., Rhodes K. J. and Cockett M. I. (1998) Distribution of heterotrimeric G-protein beta and gamma subunits in the rat brain. Neuroscience 85, 475486.
  • Bonsi P., Cuomo D., Martella G., Madeo G., Schirinzi T., Puglisi F., Ponterio G. and Pisani A. (2011) Centrality of striatal cholinergic transmission in Basal Ganglia function. Front. Neuroanat. 5, 6.
  • Calabresi P., Pisani A., Mercuri N. B. and Bernardi G. (1992) Long-term potentiation in the striatum is unmasked by removing the voltage-dependent magnesium block of NMDA receptor channels. Eur. J. Neurosci. 4, 929935.
  • Carter R. J., Lione L. A., Humby T., Mangiarini L., Mahal A., Bates G. P., Dunnett S. B. and Morton A. J. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19, 32483257.
  • Castellanos F. X., Giedd J. N., Marsh W. L. et al. (1996) Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch. Gen. Psychiatry 53, 607616.
  • Cicchetti F., Soulet D. and Freeman T. B. (2011) Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications. Brain 134, 641652.
  • Comings D. E. (2001) Clinical and molecular genetics of ADHD and Tourette syndrome. Two related polygenic disorders. Ann. N. Y. Acad. Sci. 931, 5083.
  • Corvol J. C., Muriel M. P., Valjent E., Feger J., Hanoun N., Girault J. A., Hirsch E. C. and Herve D. (2004) Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J. Neurosci. 24, 70077014.
  • Danielson P. E., Watson J. B., Gerendasy D. D., Erlander M. G., Lovenberg T. W., de Lecea L., Sutcliffe J. G. and Frankel W. N. (1994) Chromosomal mapping of mouse genes expressed selectively within the central nervous system. Genomics 19, 454461.
  • Deng Y. P., Albin R. L., Penney J. B., Young A. B., Anderson K. D. and Reiner A. (2004) Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J. Chem. Neuroanat. 27, 143164.
  • Desplats P. A., Kass K. E., Gilmartin T., Stanwood G. D., Woodward E. L., Head S. R., Sutcliffe J. G. and Thomas E. A. (2006) Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J. Neurochem. 96, 743757.
  • Durieux P. F., Bearzatto B., Guiducci S., Buch T., Waisman A., Zoli M., Schiffmann S. N. and de Kerchove d'Exaerde A. (2009) D2R striatopallidal neurons inhibit both locomotor and drug reward processes. Nat. Neurosci. 12, 393395.
  • Ena S., de Kerchove d'Exaerde A. and Schiffmann S. N. (2011) Unraveling the differential functions and regulation of striatal neuron sub-populations in motor control, reward, and motivational processes. Front. Behav. Neurosci. 5, 47.
  • Fan J., Gladding C. M., Wang L., Zhang L. Y., Kaufman A. M., Milnerwood A. J. and Raymond L. A. (2012) P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease. Neurobiol. Dis. 45, 9991009.
  • Fink J. S., Weaver D. R., Rivkees S. A., Peterfreund R. A., Pollack A. E., Adler E. M. and Reppert S. M. (1992) Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res. Mol. Brain Res. 14, 186195.
  • Gerfen C. R., Engber T. M., Mahan L. C., Susel Z., Chase T. N., Monsma F. J. Jr. and Sibley D. R. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 14291432.
  • Graybiel A. M. (2000) The basal ganglia. Curr. Biol. 10, R509R511.
  • Guo M. L., Fibuch E. E., Liu X. Y., Choe E. S., Buch S., Mao L. M. and Wang J. Q. (2010) CaMKIIalpha interacts with M4 muscarinic receptors to control receptor and psychomotor function. EMBO J. 29, 20702081.
  • Hamani C., Saint-Cyr J. A., Fraser J., Kaplitt M. and Lozano A. M. (2004) The subthalamic nucleus in the context of movement disorders. Brain 127, 420.
  • Hashimoto Y., Morisawa K., Saito H., Jojima E., Yoshida N. and Haga T. (2008) Muscarinic M4 receptor recycling requires a motif in the third intracellular loop. J. Pharmacol. Exp. Ther. 325, 947953.
  • Hodges A., Strand A. D., Aragaki A. K. et al. (2006) Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 15, 965977.
  • Hogl B., Garcia-Borreguero D., Trenkwalder C. et al. (2011) Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med. 12, 351360.
  • Ince E., Ciliax B. J. and Levey A. I. (1997) Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons. Synapse 27, 357366.
  • Jeon J., Dencker D., Wortwein G. et al. (2010) A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors. J. Neurosci. 30, 23962405.
  • Johnson P. M. and Kenny P. J. (2010) Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat. Neurosci. 13, 635641.
  • Kelly M. A., Rubinstein M., Phillips T. J. et al. (1998) Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J. Neurosci. 18, 34703479.
  • Keshavan M. S., Tandon R., Boutros N. N. and Nasrallah H. A. (2008) Schizophrenia, “just the facts”: what we know in 2008 Part 3: neurobiology. Schizophr. Res. 106, 89107.
  • Kishioka A., Fukushima F., Ito T., Kataoka H., Mori H., Ikeda T., Itohara S., Sakimura K. and Mishina M. (2009) A novel form of memory for auditory fear conditioning at a low-intensity unconditioned stimulus. PLoS ONE 4, e4157.
  • Lange K. W., Javoy-Agid F., Agid Y., Jenner P. and Marsden C. D. (1992) Brain muscarinic cholinergic receptors in Huntington's disease. J. Neurol. 239, 103104.
  • Le Merrer J., Becker J. A., Befort K. and Kieffer B. L. (2009) Reward processing by the opioid system in the brain. Physiol. Rev. 89, 13791412.
  • Luo F., Li C., Ondo W. G., Xu P., Xie W. and Le W. (2011) The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model. Sleep Med. 12, 4146.
  • Nicola S. M. (2007) The nucleus accumbens as part of a basal ganglia action selection circuit. Psychopharmacology 191, 521550.
  • Nishi A., Kuroiwa M. and Shuto T. (2011) Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neurons. Front. Neuroanat. 5, 43.
  • Samadi P., Boutet A., Rymar V. V. et al. (2013) Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of huntington's disease. Genes Brain Behav. 12, 108124.
  • Pavese N., Andrews T. C., Brooks D. J. et al. (2003) Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 126, 11271135.
  • Rinken A., Terasmaa A., Raidaru G. and Fuxe K. (2001) D2 dopamine receptor-G protein coupling. Cross-regulation of agonist and guanosine nucleotide binding sites. Neurosci. Lett. 302, 58.
  • Saka E. and Graybiel A. M. (2003) Pathophysiology of Tourette's syndrome: striatal pathways revisited. Brain Dev. 25(Suppl 1), S15S19.
  • Schilling G., Becher M. W., Sharp A. H. et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397407.
  • Schwindinger W. F., Betz K. S., Giger K. E., Sabol A., Bronson S. K. and Robishaw J. D. (2003) Loss of G protein gamma 7 alters behavior and reduces striatal alpha(olf) level and cAMP production. J. Biol. Chem. 278, 65756579.
  • Shen W., Flajolet M., Greengard P. and Surmeier D. J. (2008) Dichotomous dopaminergic control of striatal synaptic plasticity. Science 321, 848851.
  • Smith R., Chung H., Rundquist S. et al. (2006) Cholinergic neuronal defect without cell loss in Huntington's disease. Hum. Mol. Genet. 15, 31193131.
  • Takahashi H., Nogawa S., Tachibana H., Kawamura J., Abe T., Ogino Y., Kashihara K., Hamada T. and Kowa H. (2008) Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching. J. Int. Med. Res. 36, 106114.
  • Vonsattel J. P. (2008) Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol. 115, 5569.
  • Wacker J. L., Huang S. Y., Steele A. D. et al. (2009) Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease. J. Neurosci. 29, 91049114.
  • Wang Q., Mullah B., Hansen C., Asundi J. and Robishaw J. D. (1997) Ribozyme-mediated suppression of the G protein gamma7 subunit suggests a role in hormone regulation of adenylylcyclase activity. J. Biol. Chem. 272, 2604026048.
  • Wang Q., Mullah B. K. and Robishaw J. D. (1999) Ribozyme approach identifies a functional association between the G protein beta1gamma7 subunits in the beta-adrenergic receptor signaling pathway. J. Biol. Chem. 274, 1736517371.
  • Wang Q., Jolly J. P., Surmeier J. D., Mullah B. M., Lidow M. S., Bergson C. M. and Robishaw J. D. (2001) Differential dependence of the D1 and D5 dopamine receptors on the G protein gamma 7 subunit for activation of adenylylcyclase. J. Biol. Chem. 276, 3938639393.
  • Waugh J. L., Celver J., Sharma M. et al. (2011) Association between regulator of G protein signaling 9-2 and body weight. PLoS ONE 6, e27984.
  • Yin H. H. and Knowlton B. J. (2006) The role of the basal ganglia in habit formation. Nat. Rev. Neurosci. 7, 464476.
  • Yin H. H., Knowlton B. J. and Balleine B. W. (2005) Blockade of NMDA receptors in the dorsomedial striatum prevents action-outcome learning in instrumental conditioning. Eur. J. Neurosci. 22, 505512.
  • Yu Z. X., Li S. H., Evans J., Pillarisetti A., Li H. and Li X. J. (2003) Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci. 23, 21932202.
  • Zeron M. M., Hansson O., Chen N., Wellington C. L., Leavitt B. R., Brundin P., Hayden M. R. and Raymond L. A. (2002) Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33, 849860.